PepVault
/ database / GLP-1 / Amylin Co-Agonist

Amycretin

Novo single-molecule GLP-1 plus amylin agonist with striking early loss.

Evidence
emerging
Legal status
research only
Half-life
Long (days+)
Routes
subq · oral
View on Limitless LifeAdd to compare
What it is

Novo single-molecule GLP-1 plus amylin agonist with striking early loss.

Mechanism

Novo single-molecule GLP-1 plus amylin agonist with striking early loss.

Outcomes it's matched to
Safety

Educational reference only. Long-term human safety varies; consult a peptide-literate clinician.

Legal context

Investigational

1:1 GUIDANCE

Have questions about this peptide?

Get free 1:1 guidance from a peptide professional before you start. They'll help you think through dosing, stacking, and whether this fits your goals.

REQUEST A CALL →
PepVault

An outcome-driven reference for modern peptides. Educational only — not medical advice, not a sales platform, not affiliated with any clinic.

Disclaimer: PepVault is an educational resource. Nothing on this site is medical advice. Many peptides discussed are research compounds and are not approved by the FDA or equivalent agencies. Always consult a qualified clinician before starting any protocol.

© 2026 PepVault